Development
Rapid Dose Therapeutics Corp.
DOSE
CNSX
| 11/30/2023 | 08/31/2023 | ||||
|---|---|---|---|---|---|
| Revenue | -35.36% | 49.30% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -35.36% | 49.30% | |||
| Cost of Revenue | -27.90% | 16.85% | |||
| Gross Profit | -40.34% | 83.28% | |||
| SG&A Expenses | 17.65% | 51.99% | |||
| Depreciation & Amortization | 6.37% | -2.59% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 19.37% | 31.17% | |||
| Operating Income | -54.11% | -21.79% | |||
| Income Before Tax | -31.08% | -31.21% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -31.08% | -31.21% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -31.08% | -31.21% | |||
| EBIT | -54.11% | -21.79% | |||
| EBITDA | -59.47% | -27.22% | |||
| EPS Basic | -30.19% | -32.50% | |||
| Normalized Basic EPS | -30.30% | -32.00% | |||
| EPS Diluted | -30.19% | -32.50% | |||
| Normalized Diluted EPS | -30.30% | -32.00% | |||
| Average Basic Shares Outstanding | 0.46% | 0.00% | |||
| Average Diluted Shares Outstanding | 0.46% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||